Document
Drug repositioning in thyroid cancer: from point mutations to gene fusions
The diagnosis of thyroid cancer (TC) has increased dramatically in recent years. Papillary TC is the most frequent type and has shown a good prognosis. Conventional treatments for TC are surgery, hormonal therapy, radioactive iodine, chemotherapy, and targeted therapy. However, resistance to treatments is well documented in almost 20%25 of all cases. Genomic sequencing has provided valuable information to help identify variants that hinder the success of chemotherapy as well as to determine which of those represent potentially druggable targets. There is a plethora of targeted therapies for cancer, most of them directed toward point mutations; however, chromosomal rearrangements that generate fusion genes are becoming relevant in cancer but have been less explored in TC. Therefore, it is relevant to identify new potential inhibitors for genes that are recurrent in the formation of gene fusions. In this review, we focus on describing potentially druggable variants and propose both point variants and fusion genes as targets for drug repositioning in TC. Copyright
gene fusions; mutations; repurposed drugs; thyroid cancer; variants adagrasib; afatinib; alectinib; alpelisib; amivantamab; brigatinib; cabozantinib; capmatinib; ceritinib; crizotinib; dabrafenib; eltrombopag; entrectinib; ephrin receptor; guanosine triphosphatase; ipilimumab; lapatinib; larotrectinib; lorlatinib; mitogen activated protein kinase; nivolumab; osimertinib; pertuzumab; phosphatase; phosphatidylinositol; phosphatidylinositol 3 kinase; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; pioglitazone; protein kinase; protein serine threonine kinase; radioactive iodine; rituximab; sitagliptin; sotorasib; suramin; tepotinib; trametinib; vandetanib; antineoplastic activity; B cell lymphoma; brain metastasis; breast cancer; breast carcinoma; carcinogenesis; case report; cell proliferation; chemotherapy; clinical article; colorectal cancer; cytokine production; drug repositioning; drug therapy; gene; gene fusion; gene mutation; genomic instability; glioma; high throughput sequencing; hormonal therapy; human; leukemia; lung adenocarcinoma; melanoma; metastasis; molecularly targeted therapy; non insulin dependent diabetes mellitus; non small cell lung cancer; NUT midline carcinoma cell line; ovary cancer; point mutation; prognosis; sarcoma; secretory breast carcinoma; sequence analysis; Short Survey; signal transduction; single nucleotide polymorphism; thyroid cancer; tumor associated leukocyte; tumor growth; tumor microenvironment; tumor suppressor gene; uterine cervix cancer
Generically Dependent Continuant
RDF description of Drug repositioning in thyroid cancer: from point mutations to gene fusions - http://orbis.uaslp.mx/vivo/individual/scopus12523
Article
Information Content Entity
Instituto de Salud Pública; Universidad Veracruzana, UV